Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination With Venetoclax in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)

NCT06563804 is registered in ClinicalTrials.gov with Servier Bio-Innovation LLC as lead sponsor.

NCT NCT06563804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06563804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination With Venetoclax in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)
Lead sponsor
Servier Bio-Innovation LLC
Phase
Phase 1/2
Overall status
Terminated
Start date
February 25, 2025
Completion date
October 9, 2025
Enrollment
13 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelomonocytic leukemia (cmml), myelodysplastic syndrome (mds)/aml, relapsed/refractory (r/r) acute myeloid leukemia (aml)